Erasca (NASDAQ:ERAS) executives said the company sees multiple potential development paths for its RAS-targeting portfolio, highlighting early clinical activity for ERAS-0015 in lung, pancreatic and colorectal cancers during a Bank of America biotech conference session.
Jonathan Lim, Erasca’s chair
WildBrain (TSE:WILD) reported lower fiscal third-quarter revenue from continuing operations as production timing weighed on its content business, while licensing growth and a richer revenue mix helped lift margins and adjusted EBITDA.
On the company’s fiscal 2026 third-quarter earnings call, Presid
Valeura Energy (TSE:VLE) executives told shareholders at the company’s 2026 annual general meeting that the Thailand-focused producer is benefiting from higher oil prices, a growing reserve base and ongoing development work, while continuing to evaluate acquisitions and future capital returns.
Pres
Velan (TSE:VLN) reported modest sales growth and a larger year-end backlog for fiscal 2026, while management pointed to tariffs, geopolitical tensions and shifting customer delivery schedules as factors weighing on profitability and order timing.
On the company’s fourth-quarter earnings call, Chair
Wesdome Gold Mines (TSE:WDO) reported what management described as a record first quarter, supported by strong gold production and prices, while reaffirming its full-year production and cost guidance.
On the company’s earnings call for the three months ended March 31, 2026, President and CEO Anthea
Vecima Networks (TSE:VCM) said it raised its calendar 2026 growth outlook as customer demand for broadband network upgrade products strengthens, while reporting fiscal third-quarter revenue that was slightly higher than a year earlier but lower sequentially.
President and CEO Sumit Kumar said the c
